The best indicator for Medtronic (MDT)
We backtested 20 indicators across daily, weekly and hourly charts on real Medtronic (MDT) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Money Flow Index
On the daily chart, this is the strongest risk-adjusted edge we found for Medtronic (MDT) over ~53.1 years — trailing buy-and-hold by 4.0% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Money Flow Index ✓ | Daily | 8.3% | 0.5 | -64.2% | 82.1% | 56 | -4.0% |
| 2 | EMA 20/50 Cross ✓ | Weekly | 9.3% | 0.49 | -73.9% | 42.9% | 21 | -2.8% |
| 3 | Williams %R ✓ | Daily | 7.8% | 0.48 | -49.1% | 71.7% | 346 | -4.4% |
| 4 | WaveTrend (8/6/4) ✓ | Daily | 8.5% | 0.48 | -55.9% | 71.0% | 207 | -3.8% |
| 5 | SMA 50/200 Cross ✓ | Daily | 8.5% | 0.47 | -59.7% | 40.5% | 37 | -3.8% |
| 6 | EMA 50/200 Cross ✓ | Daily | 7.7% | 0.44 | -59.1% | 30.8% | 39 | -4.6% |
| 7 | Stochastic ✓ | Daily | 7.0% | 0.43 | -45.5% | 72.1% | 272 | -5.3% |
| 8 | CCI ✓ | Daily | 6.8% | 0.43 | -50.7% | 73.1% | 249 | -5.4% |
| 9 | Donchian Breakout ✓ | Weekly | 6.4% | 0.41 | -50.6% | 40.9% | 44 | -5.7% |
| 10 | RSI Trend (>50) ✓ | Weekly | 6.2% | 0.38 | -65.8% | 47.1% | 153 | -5.8% |
| 11 | Heikin-Ashi Trend | Daily | 5.9% | 0.37 | -97.1% | 44.3% | 2536 | -6.4% |
| 12 | Rate of Change ✓ | Weekly | 5.9% | 0.37 | -74.9% | 44.1% | 179 | -6.1% |
| 13 | EMA 20/50 Cross ✓ | Daily | 5.5% | 0.36 | -74.6% | 43.8% | 128 | -6.7% |
| 14 | Donchian Midline ✓ | Weekly | 5.3% | 0.35 | -79.5% | 50.3% | 147 | -6.7% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Medtronic (MDT), Money Flow Index on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.